Tabernanthalog

Tabernanthalog, often abbreviated TBG, is a simplified structural analogue of ibogaine, an alkaloid found in the iboga plant that has long attracted interest for anti-addictive effects ^[1]. Ibogaine itself is hampered by serious drawbacks, including hallucinations and a tendency to disturb heart rhythm, which have limited its medical development ^[1]. Using an approach called function-oriented synthesis, chemists in David Olson's group at UC Davis pared the ibogaine structure down to what they judged to be its essential therapeutic core and produced tabernanthalog, a water-soluble molecule that can be made in a single step and that showed far less activity at the cardiac ion channel linked to ibogaine's arrhythmia risk ^[1].

In the original report, tabernanthalog promoted the growth of cortical neurons' dendritic branches and spines, produced antidepressant-like behavior, and reduced alcohol- and heroin-seeking in rodents, all without eliciting the head-twitch response that in mice serves as a behavioral marker of a psychedelic effect ^[1]. Later work found that a single dose could reverse behavioral and circuit-level disruptions caused by unpredictable stress in mice, restoring lost dendritic spines and normalizing activity in the sensory cortex ^[2]. In a model of combined heroin and alcohol use, the compound lowered animals' motivation to seek both substances ^[3].

Tabernanthalog belongs to a group sometimes called the ibogalogs and is considered a psychoplastogen, a term for compounds that rapidly promote structural neural plasticity ^[1]. It is being pursued for possible treatment of depression and substance use disorders, and its development has been associated with the biotechnology company Delix Therapeutics ^[1]. As of the mid-2020s it remains an experimental research compound that has not entered human clinical trials; the available evidence comes entirely from cell and animal studies, and it is not an approved medicine or a dietary supplement ^[1][2].

Tabernanthalog is strictly preclinical: there are no human trials, no approval, and its safety in people is completely unknown, which is the single most important thing to hold onto. Its 5-HT2A activity means chronic exposure could in theory carry the cardiovascular or heart-valve risks seen with other serotonergic agonists, and the long-term consequences of forcing neuroplasticity are not understood. Anything sold on the grey market cannot be trusted for identity or purity. This is a lab research molecule, not a supplement. Not medical advice.

Tabernanthalog, abbreviated TBG, was designed in the laboratory of David Olson at the University of California, Davis, and introduced in a 2020 paper in Nature. Using a function-oriented synthesis approach, the researchers stripped the psychedelic alkaloid ibogaine down to what they judged to be its essential therapeutic pharmacophore, producing a water-soluble analogue that could be made in a single step. The goal was to retain ibogaine's plasticity-promoting and anti-addictive potential while eliminating its hallucinogenic effects, cardiac toxicity, and other safety liabilities. The molecule became a flagship example of engineered non-hallucinogenic psychedelics and was associated with the drug-development company Delix Therapeutics.

Tabernanthalog is held in high regard within neuroscience and psychedelic research circles as a landmark demonstration that a psychedelic scaffold can be re-engineered to promote neural plasticity without producing hallucinations. It generated substantial excitement for reported antidepressant-like effects and reductions in alcohol- and opioid-seeking behavior in rodents. At the same time, informed observers emphasize that its evidence base is entirely preclinical, that it is not available as a consumer product, and that questions remain about whether its non-hallucinogenic mechanism will deliver comparable benefits in humans. It is therefore seen as a scientifically influential prototype rather than a proven treatment.